Celldex Therapeutics (CLDX) Return on Capital Employed (2011 - 2026)

Celldex Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 62.36% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 3276.0% year-over-year to 62.36% in Q1 2026; TTM through Mar 2026 was 62.36%, a 3276.0% decrease from a year earlier, with the FY2025 full-year figure at 45.14%, down 1204.0% from the prior year.
• Return on Capital Employed fell to 62.36% in Q1 2026 per CLDX's latest filing, from 50.89% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 18.55% in Q1 2022 and bottomed at 62.36% in Q1 2026.
• The 5-year median for Return on Capital Employed is 33.66% (2022), against an average of 35.13%.
• Across the five-year window, Return on Capital Employed surged 2819 bps in 2024 and plunged 3276 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 33.66% in 2022, then plunged by 34 bps to 45.21% in 2023, then jumped by 44 bps to 25.39% in 2024, then sank by 100 bps to 50.89% in 2025, then slipped by 23 bps to 62.36% in 2026.
• Per Business Quant, the three latest CLDX Return on Capital Employed figures stand at 62.36% (Q1 2026), 50.89% (Q4 2025), and 41.07% (Q3 2025).